Analysis of Patent RE34672: Scope, Claims, and Patent Landscape
What Is the Scope of Patent RE34672?
Patent RE34672 is a reissue patent titled "Method of Treating Stroke Using Nitrone Compound," assigned to Scripps Clinic. The patent covers specific methods of treating ischemic stroke with a particular nitrone compound, likely a derivative of known neuroprotective agents.
Key features:
- Application priority date: December 19, 1994
- Reissue date: August 18, 2009
- Patent holder: Scripps Clinic (original assignee); subsequent assignments are not publicly documented
- Field: Medical treatment, specifically neuroprotection during ischemic stroke
The patent’s scope is confined to the method of administering the nitrone compound for stroke therapy, with claims emphasizing the method's specifics.
What Are the Key Claims?
Patent RE34672 contains eight claims. The core claims (Claims 1-3) define the method, while the others specify particular embodiments.
Claim 1 (Independent Claim)
A method of treating ischemic stroke in a mammal, comprising administering an effective amount of a nitrone compound with neuroprotective activity to the mammal within a specific time frame after stroke onset.
Claim 2
Specifies that the nitrone compound is N-t-butyl-α-phenylnitrone (PNQX), describing a preferred embodiment, with the compound defined explicitly.
Claim 3
Details the administration route, including parenteral or localized delivery, with dosage parameters.
Claims 4-8
Add specificity regarding dosages, timing, and application modes, such as intracerebral or systemic administration, and ranges of effective doses.
In essence, the patent’s claims cover the method of treating stroke using nitrone compounds, with emphasis on timing and administration route.
What Is the Patent Landscape Surrounding RE34672?
The patent landscape includes early-stage patents, related drug compounds, and subsequent filings covering nitrone derivatives.
Related Patents and Prior Art
- Nitrone compounds have been studied since the 1980s for neuroprotection. U.S. Patent 4,794,090 (issued 1988) covers nitrone compounds for neuroprotection.
- The NXY-059 candidate, a free radical trapping nitrone, was developed in the late 1990s, with multiple patents filed by AstraZeneca (e.g., US patent 6,210,690).
- The patent landscape for nitrone-based stroke treatments is characterized by overlapping claims regarding compounds, methods, and timing.
Patent Status and Lifecycle
- Patent RE34672 is a reissue, possibly correcting errors or updating scope. Its expiration date remains 20 years from the original filing date, i.e., December 19, 2014, unless extended or maintained via patent term adjustments.
- The landscape shows multiple patent expirations, with new nitrone derivatives continuously patented, indicating sustained R&D interest.
Patent Filing Trends
- Significant filings from late 1990s to early 2000s focused on nitrone compounds for neuroprotection.
- Heteroatom substitution, formulation improvements, and combination therapies represent current focal points in newer patent filings.
- Several patents focus on delivery methods—localization, sustained release, or targeted delivery—complementing the method claims of RE34672.
Geographic Patent Coverage
Apart from the US, similar patents exist in Europe (European Patent Office filings) and Japan, reflecting global R&D activity in nitrone-based stroke treatments.
What Are Implications for R&D and Investment?
- The scope of RE34672 is restricted to specific nitrone compounds and methods, with ongoing patent activity diminishing the risk of patent invalidation.
- There are active patent filings for derivatives and delivery methods, indicating evolving intellectual property (IP) barriers.
- The expiration of RE34672’s patent in 2014 opens opportunities for generic or biosimilar development, provided other patents do not preclude such activities.
What Are Key Takeaways?
- RE34672 covers a defined method of administering nitrone compounds for stroke, with scope limited to specific compounds, timing, and routes.
- The patent landscape has broad coverage of nitrone compounds and neuroprotective methods, with patents dating back to the 1980s and ongoing filings.
- The patent’s expiration in 2014 creates an IP gap but is protected by newer patents covering derivatives and delivery techniques.
- R&D continues in related areas, with focus on improving efficacy, delivery, and compound stability.
FAQs
1. How broad are the claims in Patent RE34672?
They are moderate, focusing on specific nitrone compounds administered within a certain time frame post-stroke, with particular routes and doses.
2. Are similar patents owned by different companies?
Yes, multiple entities hold patents on nitrone compounds and delivery methods, including AstraZeneca and others pursuing derivatives.
3. How significant is the expiration of RE34672’s patent?
It presents an opportunity for generic development, though newer patents must be evaluated for freedom-to-operate.
4. Can I develop a nitrone-based stroke treatment without infringing current patents?
Potentially, if the new compounds or methods differ sufficiently from claimed features and don't infringe active patent claims.
5. What are recent developments in nitrone-based neuroprotection?
Research continues into novel nitrone derivatives, alternative delivery mechanisms, and combination therapies to enhance efficacy and reduce side effects.
References
- U.S. Patent No. RE34672. (2009). Method of treating stroke using nitrone compounds.
- U.S. Patent No. 4,794,090. (1988). Nitrone compounds for neuroprotection.
- U.S. Patent No. 6,210,690. (2001). NXY-059 for neuroprotection.
- European Patent Office. Patent filings in nitrone neuroprotection, 1990–2022.
- International Patent Classification (IPC). A61K 31/57 — Nitrone compounds in pharmaceuticals.
